Sinopharm Group Co. Ltd.

SZSC:1099 Stock Report

Market Cap: HK$62.7b

Sinopharm Group Valuation

Is 1099 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 1099 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 1099 (HK$20.1) is trading below our estimate of fair value (HK$55.17)

Significantly Below Fair Value: 1099 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1099?

Key metric: As 1099 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 1099. This is calculated by dividing 1099's market cap by their current earnings.
What is 1099's PE Ratio?
PE Ratio6.8x
EarningsCN¥8.65b
Market CapCN¥58.43b

Price to Earnings Ratio vs Peers

How does 1099's PE Ratio compare to its peers?

The above table shows the PE ratio for 1099 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average11.5x
874 Guangzhou Baiyunshan Pharmaceutical Holdings
8x-0.4%HK$47.4b
1931 IVD Medical Holding
10.4xn/aHK$2.9b
3390 Tycoon Group Holdings
12.1xn/aHK$2.8b
1345 Shanghai Pioneer Holding
15.5xn/aHK$2.6b
1099 Sinopharm Group
6.8x4.5%HK$62.7b

Price-To-Earnings vs Peers: 1099 is good value based on its Price-To-Earnings Ratio (6.8x) compared to the peer average (11.3x).

Price to Earnings Ratio vs Industry

How does 1099's PE Ratio compare vs other companies in the HK Healthcare Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
574 Pa Shun International Holdings
2.3xn/aUS$9.47m
No more companies available in this PE range
1099 6.8xIndustry Avg. 12.6xNo. of Companies10PE01224364860+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 1099 is good value based on its Price-To-Earnings Ratio (6.8x) compared to the Hong Kong Healthcare industry average (12.7x).

Price to Earnings Ratio vs Fair Ratio

What is 1099's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1099 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio6.8x
Fair PE Ratio13.4x

Price-To-Earnings vs Fair Ratio: 1099 is good value based on its Price-To-Earnings Ratio (6.8x) compared to the estimated Fair Price-To-Earnings Ratio (13.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 1099 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentHK$20.10
HK$23.33
+16.1%
17.6%HK$29.85HK$14.85n/a15
Nov ’25HK$19.58
HK$23.33
+19.1%
17.6%HK$29.85HK$14.85n/a15
Oct ’25HK$20.80
HK$24.35
+17.1%
17.1%HK$30.69HK$15.07n/a16
Sep ’25HK$18.18
HK$24.41
+34.3%
15.3%HK$30.44HK$17.05n/a16
Aug ’25HK$18.44
HK$26.35
+42.9%
10.8%HK$30.33HK$21.05n/a16
Jul ’25HK$20.75
HK$26.44
+27.4%
11.5%HK$32.19HK$21.04n/a16
Jun ’25HK$21.20
HK$26.59
+25.4%
10.8%HK$32.36HK$21.15n/a16
May ’25HK$19.84
HK$26.58
+34.0%
10.8%HK$32.37HK$21.15n/a16
Apr ’25HK$20.05
HK$27.16
+35.5%
10.0%HK$32.22HK$21.81n/a16
Mar ’25HK$22.60
HK$27.70
+22.6%
12.9%HK$33.84HK$20.56n/a15
Feb ’25HK$20.60
HK$27.59
+33.9%
12.9%HK$33.94HK$20.96n/a14
Jan ’25HK$20.45
HK$27.37
+33.8%
15.0%HK$34.07HK$19.14n/a14
Dec ’24HK$19.18
HK$27.81
+45.0%
17.5%HK$37.25HK$18.84n/a14
Nov ’24HK$18.92
HK$27.65
+46.2%
18.1%HK$36.97HK$18.69HK$19.5813
Oct ’24HK$22.70
HK$28.64
+26.2%
16.3%HK$37.07HK$20.58HK$20.8015
Sep ’24HK$22.75
HK$28.96
+27.3%
15.9%HK$37.38HK$20.75HK$18.1815
Aug ’24HK$24.90
HK$28.88
+16.0%
17.5%HK$36.18HK$18.05HK$18.4416
Jul ’24HK$24.50
HK$28.47
+16.2%
18.2%HK$35.88HK$17.99HK$20.7516
Jun ’24HK$25.60
HK$28.60
+11.7%
18.2%HK$36.43HK$18.27HK$21.2016
May ’24HK$27.75
HK$28.17
+1.5%
17.7%HK$37.37HK$18.83HK$19.8415
Apr ’24HK$23.75
HK$26.90
+13.3%
13.2%HK$31.10HK$18.94HK$20.0515
Mar ’24HK$21.30
HK$23.12
+8.6%
20.7%HK$30.71HK$12.52HK$22.6015
Feb ’24HK$19.74
HK$23.45
+18.8%
20.9%HK$31.38HK$12.79HK$20.6015
Jan ’24HK$19.84
HK$23.42
+18.0%
20.2%HK$30.77HK$12.55HK$20.4516
Dec ’23HK$18.32
HK$22.43
+22.4%
20.7%HK$29.69HK$12.11HK$19.1815
Nov ’23HK$15.24
HK$22.25
+46.0%
20.6%HK$29.45HK$12.01HK$18.9215

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Hygeia Healthcare Holdings

HK$9.8b

Offers oncology healthcare services in the People's Republic of China.

6078

HK$15.80

7D

-11.3%

1Y

-67.2%

Hygeia Healthcare Holdings

HK$9.8b

Offers oncology healthcare services in the People's Republic of China.

6078

HK$15.80

7D

-11.3%

1Y

-67.2%

Sinopharm Group

HK$62.7b

Engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People’s Republic of China.

1099

HK$20.30

7D

1.2%

1Y

5.8%